title: Treatment of Heavily Pre-treated Metastatic Breast Cancer with Eribulin: First local experience in Sabah.
abstract: There are many options in the treatment of heavily pretreated metastatic breast cancer however none of the therapeutic agents have shown promising improvement of survival with good toxicity profile. Eribulin is a novel nontaxane microtubule dynamics inhibitor. Two recent clinical trial showed that Eribulin improves progression-free and overall survival in this subset of patients. We report our experience with using Eribulin in five patients with metastatic breast cancer either in second or third-line setting, in our centre.
authors.affiliation: Likas Hospital, Oncology and Radiotherapy Department, Karung Berkunci No 187, Kota Kinabalu, Sabah 88996, Malaysia. eeldavid@hotmail.com.
authors.forename: D W
authors.initials: DW
authors.lastname: Lee
authors.affiliation: Likas Hospital, Oncology and Radiotherapy Department, Karung Berkunci No 187, Kota Kinabalu, Sabah 88996, Malaysia.
authors.forename: D C
authors.initials: DC
authors.lastname: Teoh
authors.affiliation: Rafflesia Medical Centre, Kota Kinabalu, Sabah, Malaysia.
authors.forename: F L
authors.initials: FL
authors.lastname: Chong
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D008296:Malaysia; D009362:Neoplasm Metastasis; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides